Comparing the current results to its competitors, Pro Dex Inc reported Revenue increase in the 4 quarter 2026 by 16.65 % year on year. The sales growth was above Pro Dex Inc 's competitors' average revenue growth of 12.18 %, achieved in the same quarter.
Pro Dex Inc 's Comment on Competition and Industry Peers
The company operates in highly competitive markets serving the medical device industry. It faces competition from major medical device companies as well as the internal development and manufacturing groups of its customers. Competitors typically have greater name recognition and more extensive financial, technical, product development, and marketing resources. Competitive pressures, including new product or technology introductions by the company, its customers, or competitors, may result in price reductions or loss of market share, which could adversely impact the company's business, results of operations, and financial condition. There is no assurance that the company's products and services will achieve broad market acceptance or successfully compete with other products targeting the same customers.
Overall company sales advanced by 16.65 % Pro Dex Inc outperformed its competitors in this segment and improved market share, to approx. 0.19 %. << More on PDEX Market Share.
*Market share is calculated based on total revenue.
Apyx Medical Corporation follows a business model that centers around the development, manufacturing, and marketing of medical devices used in the field of aesthetics and surgical markets. The company focuses on creating innovative products that improve patient outcomes and enhance the effectiveness of surgical procedures. Apyx Medical Corporation sells its devices primarily through a direct sales force in the United States, while utilizing a combination of direct sales representatives and distributors in international markets.
Neuropace Inc's business model revolves around the development and commercialization of medical devices for the treatment of neurological disorders, primarily focusing on epilepsy.
Nuo Therapeutics Inc's business model revolves around developing and commercializing innovative biologic therapies aimed at improving healthcare outcomes for patients. They focus on the research, development, and marketing of new therapeutic products, primarily in the wound care sector.
Pulse Biosciences Inc's business model focuses on the development and commercialization of proprietary technology platforms, specifically in the field of nano-pulse stimulation (NPS) technology.
Sources:
Pro dex Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pro dex Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
